Partial
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Label-aligned content is present for hepatic adverse effects and evaluation/monitoring of abnormal liver function tests, but multiple safety-related claims add unsupported specifics (monitoring timing/frequency, biomarker interpretation, comparative incidence, dose-dependent/idiosyncratic risk framing, pre-existing liver disease susceptibility) and one discontinuation claim is not clearly supported as an automatic action by the provided label text.
Category Scores
Accurate Statements
Tigecycline has been associated with liver enzyme elevations.
5.4 Hepatic Adverse Effects: 'Increases in total bilirubin concentration, prothrombin time and transaminases have been seen...'
Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy.
5.4 Hepatic Adverse Effects: 'Patients who develop abnormal liver function tests... should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy.'
Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients treated with tigecycline.
5.4 Hepatic Adverse Effects: 'Isolated cases of significant hepatic dysfunction and hepatic failure have been reported...'
Unsupported Statements
Monitoring liver enzymes during tigecycline therapy is crucial to detect potential liver damage early.
5.4 supports monitoring abnormal liver function tests and evaluation, but the provided label text does not explicitly state 'crucial' or 'detect early.'
Tigecycline is associated with a higher incidence of liver enzyme elevations compared to other antibiotics.
No such comparative incidence statement is present in the provided label section 5.4.
Tigecycline can cause liver damage at high doses (dose-dependent toxicity).
No dose-dependent toxicity language is present in the provided label section 5.4.
Some patients may experience idiosyncratic reactions to tigecycline that can cause liver damage.
No 'idiosyncratic reactions' framing is present in the provided label section 5.4.
Patients with pre-existing liver disease may be more susceptible to liver damage during tigecycline therapy.
The provided label excerpt does not state increased susceptibility based on pre-existing liver disease.
Monitoring liver enzymes during tigecycline therapy involves regular blood tests to check for elevated liver enzyme levels.
Label 5.4 refers to 'abnormal liver function tests' and monitoring worsening hepatic function, but does not specify 'regular' testing or a schedule.
Alanine aminotransferase (ALT) measures the level of ALT in the blood and is an indicator of liver damage.
The provided label excerpt does not mention ALT or give biomarker interpretation definitions.
Aspartate aminotransferase (AST) measures the level of AST in the blood and is another indicator of liver damage.
The provided label excerpt does not mention AST or give biomarker interpretation definitions.
Alkaline phosphatase (ALP) measures the level of ALP in the blood and is an indicator of bile duct damage.
The provided label excerpt does not mention ALP or bile duct-specific interpretation.
According to the manufacturer's guidelines, liver enzymes should be monitored at baseline during tigecycline therapy.
No baseline monitoring instruction is present in the provided label excerpts.
According to the manufacturer's guidelines, liver enzymes should be monitored 3-5 days after initiation of tigecycline therapy.
No 3-5 day post-initiation monitoring timing is present in the provided label excerpts.
According to the manufacturer's guidelines, liver enzymes should be monitored at the end of tigecycline therapy.
No end-of-therapy monitoring timing is present in the provided label excerpts.
Liver damage during tigecycline therapy can lead to liver failure, which can be life-threatening.
5.4 reports hepatic failure and provides no explicit 'life-threatening' characterization in the supplied label text.
Contradictions
Low
AI Statement
Tigecycline therapy should be discontinued if liver enzymes are elevated.
Label Reference
5.4 Hepatic Adverse Effects
Important Omissions
Label does not mandate discontinuation solely due to elevated liver enzymes; it instructs monitoring for worsening hepatic function and evaluating risk/benefit of continuing therapy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported additions (e.g., automatic discontinuation, specific monitoring timing/frequency, biomarker interpretation, comparative incidence and dose/idiosyncratic risk framing) could lead to inaccurate clinical expectations relative to the provided label language.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Multiple claims introduce specific monitoring schedules, biomarker definitions, comparative incidence, dose-dependent/idiosyncratic susceptibility, and a discontinuation rule that are not supported by the provided label excerpt.
Suggested Improvement
Restrict statements about hepatic risk to 5.4 language: reports of transaminase/bilirubin/prothrombin time increases, isolated hepatic dysfunction/failure, and that patients with abnormal liver function tests should be monitored for worsening hepatic function and evaluated for risk/benefit of continuing therapy; avoid specific timing/frequency and biomarker interpretation not present in the provided label.